Related Experiment Video
Updated: May 23, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Gracillin suppresses cancer progression through inducing Merlin/LATS protein-protein interaction and activating Hippo
Jin-Xuan Su1, Hai-Xia Zhou1, Zhi-Jing Zhang1,2
1State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Abstract:
Gene therapy, epigenetic therapies, natural compounds targeted therapy, photodynamic therapy, nanoparticles, and precision medicines are becoming available to diagnose and treat cancer. Gracillin, a natural steroidal saponin extracted from herbs, has shown potent efficacy against a range of malignancies. In this study, we investigated the molecular anticancer mechanisms of gracillin. We showed that gracillin dose-dependently suppressed proliferation, migration, and invasion in breast cancer, liver cancer, and glioblastoma cells with IC50 values around 1 μM, which were associated with MST-independent activation of Hippo signaling pathway and subsequent decreased YAP activity. We demonstrated that gracillin activated the Hippo signaling by inducing Merlin/LATS protein-protein interaction (PPI). A competitive inhibitory peptide (SP) derived from the binding interface of the PPI, disrupted the interaction, abolishing the anticancer activity of gracillin. In nude mice bearing MDA-MB-231, HCCLM3, or U87MG xenograft tumor, administration of gracillin (5, 10 mg·kg-1·d-1, i.g. for 21 days) dose-dependently suppressed the tumor growth, associated with the induced Merlin/LATS PPI, activated Hippo signaling, as well as decreased YAP activity in tumor tissues. Our data demonstrate that gracillin is an efficacious therapeutic agent for cancer treatment, induction of Merlin/LATS PPI might provide proof-of-concept in developing therapeutic agent for cancer treatment.
Insights
Gracillin, a natural compound, effectively inhibits cancer cell growth and tumor development by activating the Hippo signaling pathway through Merlin/LATS protein interactions. This natural targeted therapy offers a promising new avenue for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Natural Product Chemistry
Background:
- Emerging cancer therapies include gene therapy, epigenetic modifications, natural compounds, and precision medicine.
- Gracillin, a steroidal saponin from herbs, exhibits significant anticancer properties against various malignancies.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying gracillin's anticancer effects.
- To investigate gracillin's impact on the Hippo signaling pathway and YAP activity.
Main Methods:
- In vitro studies using breast cancer, liver cancer, and glioblastoma cell lines.
- In vivo xenograft tumor models in nude mice.
- Analysis of protein-protein interactions (PPI) and signaling pathway activation.
Main Results:
- Gracillin suppressed cancer cell proliferation, migration, and invasion (IC50 ≈ 1 μM).
- Gracillin activated the Hippo signaling pathway via Merlin/LATS PPI, reducing YAP activity.
- Gracillin administration inhibited xenograft tumor growth in vivo.
Conclusions:
- Gracillin demonstrates potent anticancer efficacy through the induction of Merlin/LATS PPI and Hippo signaling activation.
- Targeting Merlin/LATS PPI represents a viable strategy for developing novel cancer therapeutics.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
The Intrinsic Apoptotic Pathway

